{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:43:43Z","timestamp":1792421023191,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The cardiovascular system is among the least systems affected by immune-related adverse events. We report a rare life-threatening case of pembrolizumab-induced myocarditis with complete atrioventricular block and concomitant myositis in a metastatic bladder cancer patient.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>An 82-year-old Caucasian female with invasive urothelial carcinoma, started on first-line pembrolizumab, was admitted four days after receiving her second dose for severe asthenia, diffuse muscle aches, neck pain, and lethargy. In the emergency department, she had several episodes of bradycardia reaching 40 beats per minute associated with general discomfort and fatigue. Electrocardiography showed a third-degree atrioventricular heart block, while the patient remained normotensive. Cardiac damage parameters were altered with elevated levels of creatine phosphokinase of 8930\u00a0U\/L, suggestive of immune checkpoint inhibitor-induced myositis, and troponin T of 1.060\u00a0ng\/mL. Transthoracic echocardiography showed a preserved ejection fraction. Pembrolizumab-induced myocarditis was suspected. Therefore, treatment was initiated with high-dose glucocorticoids for 5\u00a0days, followed by a long oral steroid taper. A pacemaker was also implanted. Treatment resulted in the resolution of heart block and a decrease in creatine phosphokinase to the normal range.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Life-threatening cardiac adverse events in the form of myocarditis may occur with pembrolizumab use, warranting vigilant cardiac monitoring. Troponin monitoring in high-risk patients, along with baseline echocardiography may help identify this complication promptly to prevent life-threatening consequences.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-024-04397-3","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T01:01:58Z","timestamp":1708563718000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pembrolizumab-induced myocarditis with complete atrioventricular block and concomitant myositis in a metastatic bladder cancer patient: a case report and review of the literature"],"prefix":"10.1186","volume":"18","author":[{"given":"R.","family":"Saad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ghaddar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5443-7780","authenticated-orcid":false,"given":"R. M.","family":"Zeenny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"issue":"10","key":"4397_CR1","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1200\/JCO.20.03420","volume":"39","author":"SM Smith","year":"2021","unstructured":"Smith SM, Wachter K, Burris HA 3rd, et al. Clinical cancer advances 2021: ASCO\u2019s report on progress against cancer. J Clin Oncol. 2021;39(10):1165\u201384. https:\/\/doi.org\/10.1200\/JCO.20.03420.","journal-title":"J Clin Oncol"},{"issue":"4","key":"4397_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364. https:\/\/doi.org\/10.1038\/nrc3239.","journal-title":"Nat Rev Cancer"},{"key":"4397_CR3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139\u201348. https:\/\/doi.org\/10.1016\/j.ejca.2015.11.016.","journal-title":"Eur J Cancer"},{"issue":"3","key":"4397_CR4","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3390\/cancers12030738","volume":"12","author":"RK Vaddepally","year":"2020","unstructured":"Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers. 2020;12(3):738. https:\/\/doi.org\/10.3390\/cancers12030738.","journal-title":"Cancers"},{"issue":"2","key":"4397_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/CMR.0000000000000314","volume":"27","author":"J Behling","year":"2017","unstructured":"Behling J, Kaes J, M\u00fcnzel T, Grabbe S, Loquai C. New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma. Melanoma Res. 2017;27(2):155\u20138. https:\/\/doi.org\/10.1097\/CMR.0000000000000314.","journal-title":"Melanoma Res"},{"issue":"4","key":"4397_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000247","volume":"2","author":"G Varricchi","year":"2017","unstructured":"Varricchi G, Galdiero MR, Marone G, et al. Cardiotoxicity of immune checkpoint inhibitors. ESMO Open. 2017;2(4): e000247. https:\/\/doi.org\/10.1136\/esmoopen-2017-000247.","journal-title":"ESMO Open"},{"issue":"16","key":"4397_CR7","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.037.","journal-title":"J Am Coll Cardiol"},{"issue":"10124","key":"4397_CR8","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391(10124):933. https:\/\/doi.org\/10.1016\/S0140-6736(18)30533-6.","journal-title":"Lancet"},{"key":"4397_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.105866","volume":"76","author":"Q Fan","year":"2019","unstructured":"Fan Q, Hu Y, Yang C, Zhao B. Myocarditis following the use of different immune checkpoint inhibitor regimens: a real-world analysis of post-marketing surveillance data. Int Immunopharmacol. 2019;76: 105866. https:\/\/doi.org\/10.1016\/j.intimp.2019.105866.","journal-title":"Int Immunopharmacol"},{"key":"4397_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eucr.2020.101145","volume":"31","author":"M Takai","year":"2020","unstructured":"Takai M, Kato D, Iinuma K, et al. Simultaneous pembrolizumab-induced myasthenia gravis and myocarditis in a patient with metastatic bladder cancer: a case report. Urol Case Rep. 2020;31: 101145. https:\/\/doi.org\/10.1016\/j.eucr.2020.101145.","journal-title":"Urol Case Rep"},{"key":"4397_CR11","doi-asserted-by":"publisher","DOI":"10.1536\/ihj.20-162.10.1536\/ihj.20-162","author":"H Matsui","year":"2020","unstructured":"Matsui H, Kawai T, Sato Y, et al. A fatal case of myocarditis following myositis induced by pembrolizumab treatment for metastatic upper urinary tract urothelial carcinoma. Int Heart J. 2020. https:\/\/doi.org\/10.1536\/ihj.20-162.10.1536\/ihj.20-162.","journal-title":"Int Heart J"},{"issue":"3","key":"4397_CR12","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1080\/01676830.2018.1490439","volume":"38","author":"JB Hellman","year":"2019","unstructured":"Hellman JB, Traynis I, Lin LK. Pembrolizumab and epacadostat induced fatal myocarditis and myositis presenting as a case of ptosis and ophthalmoplegia. Orbit. 2019;38(3):244\u20137. https:\/\/doi.org\/10.1080\/01676830.2018.1490439.","journal-title":"Orbit"},{"issue":"2","key":"4397_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging. CA Cancer J Clin. 2017;67(2):93\u20139. https:\/\/doi.org\/10.3322\/caac.21388.","journal-title":"CA Cancer J Clin"},{"key":"4397_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/ITT.S141577","volume":"6","author":"M Davies","year":"2017","unstructured":"Davies M, Duffield EA. Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. Immunotargets Ther. 2017;6:51\u201371. https:\/\/doi.org\/10.2147\/ITT.S141577.","journal-title":"Immunotargets Ther"},{"issue":"18","key":"4397_CR15","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749\u201355. https:\/\/doi.org\/10.1056\/NEJMoa1609214.","journal-title":"N Engl J Med"},{"issue":"1","key":"4397_CR16","doi-asserted-by":"publisher","first-page":"17324","DOI":"10.1038\/s41598-021-96467-5","volume":"11","author":"T Makunts","year":"2021","unstructured":"Makunts T, Saunders IM, Cohen IV, et al. Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data. Sci Rep. 2021;11(1):17324. https:\/\/doi.org\/10.1038\/s41598-021-96467-5.","journal-title":"Sci Rep"},{"key":"4397_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.835510","volume":"13","author":"H Dong","year":"2022","unstructured":"Dong H, Qi Y, Kong X, Wang Z, Fang Y, Wang J. PD-1\/PD-L1 inhibitor-associated myocarditis: epidemiology, characteristics, diagnosis, treatment, and potential mechanism. Front Pharmacol. 2022;13: 835510. https:\/\/doi.org\/10.3389\/fphar.2022.835510.","journal-title":"Front Pharmacol"},{"issue":"12","key":"4397_CR18","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579\u201389. https:\/\/doi.org\/10.1016\/S1470-2045(18)30608-9.","journal-title":"Lancet Oncol"},{"issue":"10145","key":"4397_CR19","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S0140-6736(18)31542-3","volume":"392","author":"SG Al-Kindi","year":"2018","unstructured":"Al-Kindi SG, Oliveira GH. Reporting of immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;392(10145):382\u20133. https:\/\/doi.org\/10.1016\/S0140-6736(18)31542-3.","journal-title":"Lancet"},{"issue":"2","key":"4397_CR20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345. https:\/\/doi.org\/10.1038\/clpt.1981.154.","journal-title":"Clin Pharmacol Ther"},{"issue":"3 Suppl 1","key":"4397_CR21","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.amepre.2013.10.029","volume":"46","author":"MC White","year":"2014","unstructured":"White MC, Holman DM, Boehm JE, Peipins LA, Grossman M, Henley SJ. Age and cancer risk: a potentially modifiable relationship. Am J Prev Med. 2014;46(3 Suppl 1):S7\u201315. https:\/\/doi.org\/10.1016\/j.amepre.2013.10.029.","journal-title":"Am J Prev Med"},{"issue":"17","key":"4397_CR22","doi-asserted-by":"publisher","first-page":"4992","DOI":"10.1158\/1078-0432.CCR-16-3066","volume":"23","author":"CS Baik","year":"2017","unstructured":"Baik CS, Rubin EH, Forde PM, et al. Immuno-oncology clinical trial design: limitations, challenges, and opportunities. Clin Cancer Res. 2017;23(17):4992\u20135002. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-3066.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4397_CR23","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013757","volume":"9","author":"N Palaskas","year":"2020","unstructured":"Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc. 2020;9(2): e013757. https:\/\/doi.org\/10.1161\/JAHA.119.013757.","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"4397_CR24","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis [published correction appears in JAMA Oncol. 2018;4(12):1792]. JAMA Oncol. 2018;4(12):1721\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923.","journal-title":"JAMA Oncol"},{"issue":"2","key":"4397_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","volume":"140","author":"MP Bonaca","year":"2019","unstructured":"Bonaca MP, Olenchock BA, Salem JE, et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation. 2019;140(2):80\u201391. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034497.","journal-title":"Circulation"},{"key":"4397_CR26","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2147\/vhrm.s5306","volume":"6","author":"MA Daubert","year":"2010","unstructured":"Daubert MA, Jeremias A. The utility of troponin measurement to detect myocardial infarction: review of the current findings. Vasc Health Risk Manag. 2010;6:691\u20139. https:\/\/doi.org\/10.2147\/vhrm.s5306.","journal-title":"Vasc Health Risk Manag"},{"issue":"36","key":"4397_CR27","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update [published correction appears in J Clin Oncol. 2022 Jan 20;40(3):315]. J Clin Oncol. 2021;39(36):4073\u2013126. https:\/\/doi.org\/10.1200\/JCO.21.01440.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4397_CR28","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s00432-019-02927-x","volume":"145","author":"SA Atallah-Yunes","year":"2019","unstructured":"Atallah-Yunes SA, Kadado AJ, Kaufman GP, Hernandez-Montfort J. Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases. J Cancer Res Clin Oncol. 2019;145(6):1527\u201357.","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-024-04397-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-024-04397-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-024-04397-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T01:02:14Z","timestamp":1708563734000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-024-04397-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4397"],"URL":"https:\/\/doi.org\/10.1186\/s13256-024-04397-3","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,22]]},"assertion":[{"value":"9 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The author(s) indicated no potential conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"107"}}